Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Work In Process (2016 - 2022)

Historic Work In Process for Usana Health Sciences (USNA) over the last 12 years, with Q3 2022 value amounting to $8.0 million.

  • Usana Health Sciences' Work In Process fell 743.74% to $8.0 million in Q3 2022 from the same period last year, while for Jul 2022 it was $8.0 million, marking a year-over-year decrease of 743.74%. This contributed to the annual value of $9.6 million for FY2022, which is 371.64% down from last year.
  • Usana Health Sciences' Work In Process amounted to $8.0 million in Q3 2022, which was down 743.74% from $9.7 million recorded in Q2 2022.
  • Usana Health Sciences' Work In Process' 5-year high stood at $14.5 million during Q4 2018, with a 5-year trough of $8.0 million in Q3 2022.
  • For the 5-year period, Usana Health Sciences' Work In Process averaged around $10.7 million, with its median value being $10.0 million (2018).
  • Its Work In Process has fluctuated over the past 5 years, first surged by 7119.73% in 2018, then plummeted by 3912.3% in 2020.
  • Usana Health Sciences' Work In Process (Quarter) stood at $14.5 million in 2018, then dropped by 16.39% to $12.1 million in 2019, then decreased by 29.85% to $8.5 million in 2020, then grew by 22.14% to $10.4 million in 2021, then decreased by 23.0% to $8.0 million in 2022.
  • Its last three reported values are $8.0 million in Q3 2022, $9.7 million for Q2 2022, and $9.6 million during Q1 2022.